- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Consolidated Financial Results: Q3 FY25**
Solara Active Pharma Sciences has reported consolidated revenues of ₹3,018 crore, marking a robust 21% year-over-year growth despite a 13% decline from the previous quarter. The significant increase in revenue can be attributed to a strategic shift towards profitable products and an improved mix in regulated markets, which now contribute 76% of total revenues.
Gross margins improved to 55.4%, up by 490 basis points sequentially, and substantially higher than the 13% reported in the same quarter last year. This improvement reflects the company's rigorous focus on margin expansion initiatives and the elimination of non-profitable business lines.
Net profit for the quarter stands at ₹81 crore, with earnings per share (EPS) of ₹1.26. Operational efficiency continues to be a priority, showcased by an EBITDA margin of 19.6%, an increase of 180 basis points from the last quarter. The company is maintaining its full-year EBITDA guidance, aiming for ₹2,300 to ₹2,600 crore, emphasizing overall financial health and cost management.
**Strategic Position and Outlook:**
The board has given in-principle approval to explore a demerger of the CRAMS and Polymers business into a separate entity, aimed at enhancing focus and unlocking shareholder value. This move is expected to strengthen Solara's balance sheet and provide distinct growth avenues for both businesses.
**Investor Insight:**
With solid performance amidst challenges, Solara is well-positioned for continued growth. The combination of revenue increase, margin enhancement, and strategic demerger proposals creates an optimistic outlook. Hence, a favorable view on the stock’s performance is warranted.
All announcements from Solara Active Pharma Sciences Limited